-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Downgrades Passage Bio to Neutral, Lowers Price Target to $7

Benzinga·04/21/2026 15:59:10
Listen to the news
Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $21 to $7.